Clinical Trials

83 enrolled

Breast Neoplasms

NCT07203729 2026-03-16

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

184 enrolled

Breast Neoplasms

NCT06802757 2026-02-25

PRISM-TNBC

72 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07245797 2025-11-24

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC

164 enrolled

Breast Neoplasms

NCT04216472 2025-09-30

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

6 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04138719 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

520 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01463072 2025-07-28

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

40 enrolled 17 charts

Breast Neoplasms

NCT06441890 2025-07-14

BRE-10

28 enrolled

Breast Neoplasms

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

72 enrolled

Breast Neoplasms

NCT02788981 2025-06-10

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

29 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06964906 2025-05-11

NeoHunter

140 enrolled

Breast Neoplasms

NCT01525966 2025-03-03

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

67 enrolled 12 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01815242 2025-02-27

ADAPT

336 enrolled

Breast Neoplasms

NCT02752685 2025-01-29

Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

70 enrolled 7 charts

Breast Neoplasms

NCT00618657 2024-02-28

Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

127 enrolled 12 charts

Breast Neoplasms

NCT06165900 2024-01-03

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

136 enrolled

Breast Neoplasms

NCT04734262 2023-11-18

SPARK

98 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03961698 2023-08-14

MARIO-3

91 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT02322814 2023-04-13

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

169 enrolled 31 charts

Breast Neoplasms

NCT01036087 2023-03-30

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

47 enrolled 13 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01565499 2023-03-30

Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer

83 enrolled 24 charts

Breast Neoplasms

NCT05233696 2022-12-06

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02229149 2022-12-02

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

33 enrolled

Breast Neoplasms

NCT03907800 2022-10-27

NeoPATH

100 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05491694 2022-08-08

HIFU

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05444998 2022-07-06

Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer

20 enrolled

Breast Neoplasms

NCT01847001 2021-09-10

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

10 enrolled 12 charts

Breast Neoplasms

NCT03289819 2021-04-08

NIB

53 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02685059 2021-02-15

GeparNuevo

174 enrolled

Breast Neoplasms

NCT04066790 2020-05-19

Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

12 enrolled

Breast Neoplasms

NCT04194684 2019-12-11

Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer

108 enrolled

Breast Neoplasms

NCT00394082 2019-11-25

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

50 enrolled 17 charts

Breast Neoplasms

NCT00456846 2019-11-22

First Line Therapy for Patients With Metastatic Breast Cancer

123 enrolled 19 charts

Breast Neoplasms

NCT02598310 2019-08-28

Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer

30 enrolled

Breast Neoplasms

NCT03959397 2019-05-22

Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer

250 enrolled

Breast Neoplasms

NCT00254592 2019-02-28

Neoadjuvant Treatment of Breast Cancer

43 enrolled 7 charts

Breast Neoplasms

NCT00733408 2018-12-04

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

59 enrolled 14 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00944047 2018-04-23

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

32 enrolled 7 charts

Breast Neoplasms

NCT02783222 2018-01-10

EFFECT

160 enrolled

Breast Neoplasms

NCT00821964 2018-01-02

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

15 enrolled 11 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00407888 2017-08-31

Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery

60 enrolled 11 charts

Breast Neoplasms

NCT01830244 2017-07-02

Neonab

60 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT01763710 2016-03-29

neurabrax

60 enrolled

Breast Neoplasms, Neurotoxicity Syndromes

NCT01432223 2015-04-22

Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab

46 enrolled

Breast Neoplasms

NCT00392392 2013-09-20

Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer

29 enrolled 5 charts

Breast Neoplasms

NCT01416558 2013-05-22

Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)

66 enrolled

Breast Neoplasms

NCT00777673 2013-01-04

Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

60 enrolled

Breast Neoplasms

NCT01625429 2012-11-09

Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer

30 enrolled

Breast Neoplasms

NCT00479856 2012-06-05

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

9 enrolled 7 charts